Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Curr Opin Virol. 2021 Dec 18;52:148–160. doi: 10.1016/j.coviro.2021.12.005

Figure 4. Antibody-dependent enhancement of pE60 variants.

Figure 4.

MAb glycovariants were serially diluted and mixed with DENV-2. The mAb and virus mixture was then added to FcγR-expressing K562 cells. Cells were fixed, permeabilized and stained with anti-DENV E antibody 4G2 48 hr later, and analyzed by flow cytometry for DENV infection of cells. (Adapted from reference [86] with permission)